CDCP1 and neoplasm: Because blocking TPI demalonylation enhances its activity and resets the cellular metabolism toward glycolysis, therapeutics that target the metabolic “Achilles heel” of CDCP1+ CSCs by inhibiting TPI demalonylation in parallel to tumor debulking by chemotherapy may be required for optimal therapeutic specificity, yielding the most durable tumor remission in muKras CRCs.